Enveric Biosciences EPS ENVB

Diluted earnings per share by quarter and over the last twelve months, from 2010.

Enveric Biosciences' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q2 FY26, it was −$0.76.

Earnings per share over time

Each fiscal year is the twelve months to its fourth quarter.

Quarter	Ended	EPS	On a year earlier	Last 12 months
Q2 FY26	Jun 30, 2026	−$0.76	n/a	n/a
Q1 FY26	Mar 31, 2026	−$1.08	n/a	n/a
Q3 FY25	Sep 30, 2025	−$10.81	n/a	−$94.76
Q2 FY25	Jun 30, 2025	−$11.65	n/a	−$127.05
Q1 FY25	Mar 31, 2025	−$14.58	n/a	−$160.04
Q4 FY24	Dec 31, 2024	−$57.72	n/a	−$255.98
Q3 FY24	Sep 30, 2024	−$43.10	n/a	−$216.26
Q2 FY24	Jun 30, 2024	−$44.64	n/a	−$188.76
Q1 FY24	Mar 31, 2024	−$110.52	n/a	−$180.60
Q4 FY23	Dec 31, 2023	−$18.00	n/a	−$97.80
Q3 FY23	Sep 30, 2023	−$15.60	n/a	−$130.68
Q2 FY23	Jun 30, 2023	−$36.48	n/a	−$132.60

Companies in Healthcare nearest Enveric Biosciences' size, closest first, today.

Company	EPS, 12 months	Growth
ENVBEnveric Biosciences	n/m
NEPHNephros	$0.16	+33% a year
ATNMActinium Pharmaceuticals	$0.36
APTAlpha Pro Tech	$0.41	+24% a year
Peer median	$0.36

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.